LY294002 is a PI3K inhibitor that has demonstrated potent anti-tumor activity (Hu et al., 2000; Bar et al., 2005; Chang et al., 2015; Abdallah et al., 2020). This evidence concerns the gene PIK3CD and neoplasm.